June 1, 2016
Phosphagenics initiates placebo- controlled study for dairy cattle
Australian biotechnology company, Phosphagenics Limited, has announced the initiation of the first site in its randomised, placebo-controlled, blinded study assessing the efficacy of a TPM® formulation in dairy cattle.
Animal health and nutrition business general manager, Dr Roksan Libinaki, said: "This is an important next step in Phosphagenics' Animal Health and Nutrition research programme. This study will assess the potential for TPM® to enhance milk quality and conception rates in dairy cattle, both commercially important issues to the industry."
The study, a placebo-controlled, split-herd design, is being conducted on-farm under commercial dairy conditions for a period of 12 months and is designed to allow scope for additional sites to be added.
The study will determine the effects of the TPM® formulation on milk quality and fertility end-points during the most critical lactation and production periods. The experimental design, using a split-herd blinded approach, will account for any environmental variables or on-farm practices that may change during the conduct of the study.
The study will also provide information to assist with regulatory approvals in various jurisdictions, while providing additional efficacy data to support partners / licensees.
Completion is targeted for the fourth quarter of 2017.